HRP20141258T1 - 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat - Google Patents

6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat Download PDF

Info

Publication number
HRP20141258T1
HRP20141258T1 HRP20141258AT HRP20141258T HRP20141258T1 HR P20141258 T1 HRP20141258 T1 HR P20141258T1 HR P20141258A T HRP20141258A T HR P20141258AT HR P20141258 T HRP20141258 T HR P20141258T HR P20141258 T1 HRP20141258 T1 HR P20141258T1
Authority
HR
Croatia
Prior art keywords
compound
methylbutyl
piperidinyl
dihydro
oxy
Prior art date
Application number
HRP20141258AT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Hermann Gibbon
Amanda Lucas
Stephen Andrew Hermitage
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of HRP20141258T1 publication Critical patent/HRP20141258T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
HRP20141258AT 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat HRP20141258T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
EP11709025.8A EP2534149B1 (en) 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate

Publications (1)

Publication Number Publication Date
HRP20141258T1 true HRP20141258T1 (hr) 2015-02-27

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141258AT HRP20141258T1 (hr) 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat

Country Status (23)

Country Link
US (1) US8703754B2 (enExample)
EP (1) EP2534149B1 (enExample)
JP (1) JP5922587B2 (enExample)
KR (1) KR101773541B1 (enExample)
CN (1) CN102753553B (enExample)
AU (1) AU2011214468B2 (enExample)
BR (1) BR112012018904A2 (enExample)
CA (1) CA2786973C (enExample)
DK (1) DK2534149T3 (enExample)
EA (1) EA021048B1 (enExample)
ES (1) ES2525826T3 (enExample)
HR (1) HRP20141258T1 (enExample)
IL (1) IL220845A (enExample)
ME (1) ME01926B (enExample)
MX (1) MX2012009316A (enExample)
PL (1) PL2534149T3 (enExample)
PT (1) PT2534149E (enExample)
RS (1) RS53745B1 (enExample)
SG (1) SG182471A1 (enExample)
SI (1) SI2534149T1 (enExample)
SM (1) SMT201400196B (enExample)
WO (1) WO2011098452A1 (enExample)
ZA (1) ZA201205995B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
JP2014520874A (ja) * 2011-07-22 2014-08-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組成物
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
WO2014081645A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
CA2959506C (en) * 2014-08-29 2022-10-18 Corium International, Inc. Microstructure array for delivery of active agents
BR112017009648A2 (pt) * 2014-11-13 2017-12-19 Glaxosmithkline Biologicals Sa composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
WO2020110584A1 (ja) * 2018-11-28 2020-06-04 株式会社島津製作所 アゾ化合物の分析方法
WO2025143921A1 (ko) 2023-12-29 2025-07-03 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
CA2156408C (en) 1993-03-17 2005-02-15 Daniel C. Duan Aerosol formulation containing a polyester dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
RU2223761C2 (ru) 1999-12-27 2004-02-20 Джапан Тобакко Инк. Соединения с конденсированным кольцом и их использование в качестве лекарственных средств
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US20030215917A1 (en) 2002-04-04 2003-11-20 Mingjun Huang Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
BR0315417A (pt) 2002-10-24 2005-08-16 Glaxo Group Ltd Derivados 1-acil-pirrolidina para o tratamento de infecções virais
EP1569646A2 (en) 2002-12-13 2005-09-07 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
WO2004055016A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Pyrrolidine and azetidine compounds as ccr5 antagonists
JP2006512339A (ja) 2002-12-13 2006-04-13 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのインダン化合物
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
DE60323133D1 (de) 2002-12-13 2008-10-02 Smithkline Beecham Corp Cyclohexylverbindungen als ccr5-antagonisten
DE60324014D1 (de) 2002-12-13 2008-11-20 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
RS52931B (sr) 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
KR20070011501A (ko) 2004-04-28 2007-01-24 애로우 쎄라퓨틱스 리미티드 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
GEP20094751B (en) 2004-08-18 2009-08-10 Pfizer Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
US20060045885A1 (en) 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
PT2125792E (pt) 2007-02-19 2011-03-01 Glaxosmithkline Llc Derivados de purina como imunomoduladores
WO2008114008A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Also Published As

Publication number Publication date
EA021048B1 (ru) 2015-03-31
KR101773541B1 (ko) 2017-08-31
SG182471A1 (en) 2012-08-30
AU2011214468B2 (en) 2015-05-28
ME01926B (me) 2015-05-20
KR20120135408A (ko) 2012-12-13
US20120308609A1 (en) 2012-12-06
EP2534149B1 (en) 2014-10-15
WO2011098452A1 (en) 2011-08-18
EP2534149A1 (en) 2012-12-19
MX2012009316A (es) 2012-09-12
CN102753553B (zh) 2016-03-30
SI2534149T1 (sl) 2015-02-27
EA201290631A1 (ru) 2013-03-29
SMT201400196B (it) 2015-01-15
CN102753553A (zh) 2012-10-24
IL220845A (en) 2016-08-31
US8703754B2 (en) 2014-04-22
JP2013519645A (ja) 2013-05-30
CA2786973C (en) 2018-04-10
JP5922587B2 (ja) 2016-05-24
PL2534149T3 (pl) 2015-03-31
ZA201205995B (en) 2014-01-29
DK2534149T3 (da) 2015-01-05
CA2786973A1 (en) 2011-08-18
ES2525826T3 (es) 2014-12-30
BR112012018904A2 (pt) 2020-09-01
PT2534149E (pt) 2014-12-23
AU2011214468A1 (en) 2012-08-09
RS53745B1 (sr) 2015-06-30

Similar Documents

Publication Publication Date Title
HRP20141258T1 (hr) 6-amino-2-{[(1s)-1-metilbutil]oksi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8h-purin-8-on maleat
JP2013519645A5 (enExample)
ME02274B (me) DERIVATI PURINA ZA UPOTREBU U LEČENJU ALERGIJSKIH, INFLAMATORNIH l INFEKTIVNIH BOLESTI
BR112014001798A2 (pt) compostos de tetraciclina 9-aminometila substituídos
BRPI0720667A8 (pt) Métodos de administração de vacina
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
HRP20171512T1 (hr) Derivati betulina
HRP20191257T1 (hr) Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorbenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
WO2012007159A3 (en) Novel gastro-retentive dosage forms
RU2017112308A (ru) Композиции и способы для лечения бессонницы
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
EP2444103A4 (en) UTERUS COLON CANCER VACCINE
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
HRP20211749T1 (hr) Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom
HRP20141063T1 (hr) Cjepivo protiv hpv
JP2011529475A5 (enExample)
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
MX343600B (es) Vacunas de virus varicela zóster inactivado, métodos de producción y uso de las mismas.
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
EA200600886A1 (ru) Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции
CO6331429A2 (es) Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas
CN101244267A (zh) 一种增强微生物疫苗免疫原性的免疫制剂
RU2012116226A (ru) Бронхолитическое средство на основе простагландина
RU2017102043A (ru) Новое соединение (ks513), выделенное из pseudolysimachion rotundum var. subintegrum, композиция, содержащая указанное соединение в качестве активного ингредиента, для предотващения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких и их применение